Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 7 for:    hantavirus
Previous Study | Return to List | Next Study

Hantavirus Transmission in Households in Chile

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2011 by University of New Mexico
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of New Mexico
ClinicalTrials.gov Identifier:
NCT00533767
First received: September 20, 2007
Last updated: November 16, 2011
Last verified: November 2011
  Purpose

This study is designed to evaluate the transmission of hantavirus in Chile. It is an observational study that will look at close household contacts of people who have been diagnosed with hantavirus infections that result in a serious illness to see how frequently they become infected. Subjects who enroll in the study will donate samples of body fluids (e.g., blood, saliva, stool, urine, respiratory and vaginal secretions) to allow the researchers to see if hantavirus is present in those fluids and if so, how much. Subjects will also be interviewed to identify household conditions that may be associated with transmission. Up to 76 index cases (people who are first diagnosed with hantavirus cadiopulmonary illness) and up to 140 of their close contacts will be enrolled. Subjects will be followed for about 6 weeks.


Condition
Hantavirus Infections

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Follow Up of Household Contacts and Hantavirus Transmission Study Among Index and Additional Cases in Chile

Resource links provided by NLM:


Further study details as provided by University of New Mexico:

Primary Outcome Measures:
  • Estimate the secondary attack rate among close household contacts of index cases with hantavirus cardiopulmonary syndrome in Chile [ Time Frame: 35 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the quantity of hantavirus in bodily fluids in persons with hantavirus infection [ Time Frame: 35 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 216
Study Start Date: July 2007
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Hantavirus cardiopulmonary syndrome (HCPS) has a case fatality rate of 40-50 percent. Andes virus (ANDV) is the primary pathogen in Chile and Argentina. This is a prospective observational study to access the incidence of and risk factors associated with transmission of HCPS to close household contacts from HCPS index cases including examination of the shedding of virus in various body fluids as a factor in transmissibility. The study will enroll 76 cardiopulmonary syndrome HCPS index cases and 140 of their close household contacts, age 2 and older, at risk for contracting HCPS.

The index cases will participate for the initial visit; the household contact participants will be followed for 35 days. The primary objectives of this study are: to estimate the secondary attack rate of hantavirus infection among close household contacts of an HCPS case after one incubation period of follow up; to use personal interviews and questionnaires to assess and compare risk activities and demographic factors in close household contacts who develop HCPS with those contacts who do not identify specific high-risk activities such as exposure to saliva or respiratory secretions; to use personal interviews and questionnaires to assess and compare risk activities and demographic factors in index cases (the first case in the household) versus household contacts who do not develop HCPS; and to determine the prevalence of hantavirus in various body fluids in index patients with HCPS and in household contacts who acquire infection and consequently determine any association of presence of virus in a body fluid with phase of infection.

Both infectious virus (culture) and viral genomic RNA (quantitative RT-PCR) will be measured. The secondary objectives of this study will be: to determine the quantity of hantavirus in various body fluids in index patients with HCPS and in household contacts that acquire infection and consequently determine any association of presence of virus in a body fluid with phase of infection. Both infectious virus (culture) and viral genomic RNA (quantitative RT-PCR) will be measured; to develop a predictive statistical model where the epidemiological and the virological variables (cultures, ANDV antibodies, PCR, neutralizing antibodies, HSV 1 and 2 antibodies) could be scored and used to predict a new case within a household group; to determine the feasibility of rapid viral diagnostic testing to determine whether virologic results can be obtained sufficiently in advance of the onset of illness to permit more effective triage of patients who are indeed about to develop HCPS; and to determine the sequences of ANDV from index and additional cases to establish the extent of sequence identity from viruses within and outside of family clusters.

The primary endpoints of this study are: to determine the incidence of additional cases of hantavirus (ANDV) among close household contacts of a confirmed index case during a complete incubation period of follow up; evaluate risk activities and demographic factors associated with increased risk of transmission of ANDV between index cases and members of households and their respective index cases; measure risk activities and demographic factors associated with increased risk of acquisition of ANDV from environmental sources by comparing index cases with household contacts that do and do not develop HCPS; and determine the presence of virus and measure of viral RNA in body fluids over time in index cases and in additional cases in household contacts.

The secondary endpoints will be: to determine the most sensitive culture approach for detection of ANDV in body fluids at different stages of infection; identify the best model to predict the occurrence of an additional case within a family group; evaluate nucleotide similarity as ancillary marker to enrich or de-enrich the probability of person to person transmission of AND virus. The duration of this study is expected to be 3 years.

  Eligibility

Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

76 index cases with hantavirus cardiopulmonary syndrome and their close household contacts

Criteria

Inclusion Criteria:

Index Cases:

  1. Confirmed diagnosis, positive hantavirus IgM assay or detection of hantavirus in plasma or serum by RT-PCR.
  2. Signed informed consent form.
  3. Less than 96 hours have transpired since the diagnosis was confirmed.

Household Contact

  1. Any person, 2 years of age or older, who has been in close contact with the index case at any point from 30 days before to 7 days after the onset of symptoms in the index case.
  2. Close contact must include: sexual contact and/or deep kissing and/or slept in same bed and/or provided direct care to index case.

Exclusion Criteria:

Index Cases

  1. Index case does not have or agree to give the names of his/her close contacts.
  2. Not a suitable candidate in the opinion of the investigator.

Household Contact

  1. Confirmed current or previous infection with Andes virus.
  2. Younger than 2 years of age.
  3. Unavailable for follow up or not a suitable candidate in the opinion of the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533767

Contacts
Contact: Gregory J Mertz (505) 272-5666

Locations
Chile
Universidad Catolica de Chile Recruiting
Santiago, Chile
Contact: Marcela Ferres, M.D.    56-2-354-6823    mferres@med.puc.cl   
Contact: Pablo Vial, MD    56-2-210-1349    pvial@udd.cl   
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Gregory Mertz, MD University of New Mexico
  More Information

No publications provided

Responsible Party: University of New Mexico
ClinicalTrials.gov Identifier: NCT00533767     History of Changes
Other Study ID Numbers: 07-0013
Study First Received: September 20, 2007
Last Updated: November 16, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of New Mexico:
Hantavirus cardiopulmonary syndrome, Andes virus, Chile

Additional relevant MeSH terms:
Hantavirus Infections
Hantavirus Pulmonary Syndrome
Bunyaviridae Infections
RNA Virus Infections
Respiration Disorders
Respiratory Insufficiency
Respiratory Tract Diseases
Virus Diseases

ClinicalTrials.gov processed this record on November 27, 2014